Breast Cancer Clinical Trials in Stony Brook, New York

12 recruitingStony Brook, New York

Showing 112 of 12 trials

Recruiting
Phase 3

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 3

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Not Applicable

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

Breast CancerCognitive Impairments
NRG Oncology386 enrolled680 locationsNCT05896189
Recruiting
Phase 3

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

Breast Cancer
Exact Sciences Corporation1,800 enrolled58 locationsNCT06401421
Recruiting
Early Phase 1

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Breast CancerHER2-positive Breast CancerLocally Advanced Breast Cancer+1 more
Alison Stopeck30 enrolled1 locationNCT06220214
Recruiting
Phase 3

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Breast Cancer
Canadian Cancer Trials Group2,140 enrolled475 locationsNCT03488693
Recruiting
Not Applicable

Definitive Radiation Therapy for Inoperable Breast Cancer

Breast CancerBreast Adenocarcinoma
Alexander Stessin30 enrolled1 locationNCT07122713
Recruiting
Phase 2

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

Breast Cancer
Criterium, Inc.70 enrolled19 locationsNCT04567420
Recruiting
Phase 3

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Breast Cancer
Greenwich LifeSciences, Inc.750 enrolled161 locationsNCT05232916
Recruiting
Phase 1

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Breast CancerAdvanced CancerAdvanced Solid Tumors+1 more
OnKure, Inc.200 enrolled34 locationsNCT06239467